Viewpoint Investment Partners Corp Buys New Holdings in Royalty Pharma PLC $RPRX

Viewpoint Investment Partners Corp bought a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 8,200 shares of the biopharmaceutical company’s stock, valued at approximately $479,000.

Other institutional investors have also made changes to their positions in the company. Blue Trust Inc. boosted its position in Royalty Pharma by 173.4% during the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 437 shares during the period. CoreCap Advisors LLC increased its holdings in shares of Royalty Pharma by 89.2% in the second quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 413 shares during the last quarter. Root Financial Partners LLC acquired a new position in shares of Royalty Pharma in the third quarter valued at $62,000. Bessemer Group Inc. raised its position in shares of Royalty Pharma by 34.7% in the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 282 shares during the period. Finally, IFP Advisors Inc raised its position in shares of Royalty Pharma by 263.3% in the second quarter. IFP Advisors Inc now owns 1,188 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 861 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Marshall Urist sold 4,126 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the transaction, the executive vice president owned 270,401 shares in the company, valued at $15,826,570.53. The trade was a 27.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 208,252 shares of company stock valued at $12,324,407. Corporate insiders own 18.84% of the company’s stock.

Royalty Pharma Stock Up 1.4%

NASDAQ RPRX opened at $64.76 on Tuesday. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 0.88. Royalty Pharma PLC has a 1-year low of $35.92 and a 1-year high of $65.35. The company has a 50 day moving average of $59.84 and a 200-day moving average of $52.62. The company has a market cap of $37.24 billion, a price-to-earnings ratio of 44.66, a PEG ratio of 1.75 and a beta of 0.42.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.05. The business had revenue of $674.14 million during the quarter, compared to analysts’ expectations of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. On average, equities research analysts expect that Royalty Pharma PLC will post 5.29 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $0.2350 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.5%. Royalty Pharma’s payout ratio is currently 64.83%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on RPRX. JPMorgan Chase & Co. raised their target price on shares of Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. TD Cowen lifted their target price on shares of Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. The Goldman Sachs Group reiterated a “buy” rating and issued a $66.00 price target on shares of Royalty Pharma in a research note on Thursday, August 6th. Morgan Stanley increased their price target on shares of Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Finally, Wall Street Zen cut shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 26th. Eight research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $61.57.

About Royalty Pharma

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.